Study evaluates 'normal range' systolic bp levels after ischemic stroke and risk of recurrent stroke

November 15, 2011 in Cardiology

Among patients who experienced an ischemic stroke, systolic blood pressure levels of less than 120 mm Hg, or higher than 140 mm Hg, were associated with an increased risk of subsequent stroke, according to a study appearing in the November 16 issue of JAMA, a theme issue on cardiovascular disease. This issue is being released early online to coincide with the American Heart Association Scientific Sessions.

" prevention guidelines suggest that larger reductions in systolic blood pressure (SBP) are positively associated with a greater reduction in the risk of recurrent stroke and define an SBP level of less than 120 mm Hg as normal. However, the association of SBP maintained at such levels with risk of vascular events after a recent ischemic stroke is unclear," according to background information in the article.

Bruce Ovbiagele, M.D., M.Sc., of the University of California, San Diego, and colleagues evaluated the association of SBP maintained within a low-normal range vs. high-normal range with among patients who recently experienced an ischemic stroke. The study consisted of an observational analysis of a multicenter trial involving 20,330 patients (age 50 years or older) with recent non-cardioembolic (not due to small originating within the heart) ischemic stroke from who were recruited from 695 centers in 35 countries from September 2003 through July 2006 and followed up for 2.5 years (follow-up ended in February 2008). Patients were categorized based on their average SBP level: very low-normal (less than 120 mm Hg), low-normal (120 to less than 130 mm Hg), high-normal (130 to less than 140 mm Hg), high (140 to less than 150 mm Hg), and very high (150 mm Hg or greater).

Occurrence of the primary measured outcome (stroke) was greatest in the very high SBP level group (14.1 percent), followed by the high SBP group (8.7 percent), the very low-normal SBP group (8.0 percent), the low-normal SBP group (7.2 percent), and then the high-normal SBP group (6.8 percent). Occurrence of the secondary outcome (stroke, heart attack, or vascular death) followed a similar pattern. Rates of all-cause mortality and death due to vascular causes were highest in the very low-normal SBP group and very high SBP group.

The analyses revealed that compared with the high-normal SBP level group, the risk of stroke was significantly higher in the very low-normal SBP group, in the high SBP group, and in the very high SBP group. "Compared with the high-normal SBP level group, risks of the secondary outcome were significantly higher in the very low-normal SBP group, in the low-normal SBP group, in the high SBP group, and in the very high SBP group," the authors write.

"Our results indicate that there may indeed be thresholds of benefit or harm with regard to short-term to longer-term SBP levels after a recent non-cardioembolic ischemic stroke, and imply that clinicians regularly caring for stroke patients in the outpatient setting may need to be vigilant about how low a given patient's BP is within the normal range to promote favorable outcomes."

"In conclusion, these data are hypothesis generating and the notion that aggressively and consistently lowering BP levels within the normal range in the short term to longer term after an index ischemic stroke is not beneficial remains unproven, and will require the conduct of dedicated clinical trials comparing intensive with usual BP reduction in the stable follow-up period after a ," the authors write. They add that, in the meantime, the results of this analysis support aiming for consistent SBP levels of less than 140 mm Hg and less than 90 mm Hg for diastolic among recent patients.

More information: JAMA. 2011;306[19]:2137-2144.

Journal reference:

Provided by JAMA and Archives Journals search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Biodegradable stent proves non-inferior to drug-eluting stent

The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...

Cardiology created 8 hours ago | popularity 5 / 5 (1) | comments 0

Post-approval TAVI registry shows high rates of device success at one year

One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries to-date – reported today at EuroPCR 2013 show good clinical outcomes in routine clinical practice, ...

Cardiology created 9 hours ago | popularity not rated yet | comments 0

Antidepressant reduces stress-induced heart condition

A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.

Cardiology created 10 hours ago | popularity 5 / 5 (1) | comments 0 | with audio podcast

Study identifies superior hypertension treatment, efficacy between sexes

(Medical Xpress)—In a recent subgroup analysis of the largest blood pressure treatment trial in history, University of Alabama at Birmingham (UAB) researchers found that women and men react the same to ...

Cardiology created 18 hours ago | popularity 5 / 5 (1) | comments 0

Evaluating a new way to open clogged arteries

Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments ...

Cardiology created 18 hours ago | popularity 4.6 / 5 (5) | comments 0 | with audio podcast


If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

Drugs found to both prevent and treat Alzheimer's disease in mice

Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.